Chardan lowered the firm’s price target on Forte Biosciences (FBRX) to $61 from $64 and keeps a Buy rating on the shares. The firm updates its model after the company’s FY24 update and expectations of Celiac Disease data expected in Q2.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBRX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue